Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

2.
3.

Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.

Neurath AR, Strick N, Li YY, Jiang S.

AIDS Res Hum Retroviruses. 1993 Dec;9(12):1195-208.

PMID:
8142138
5.

Cross-reactivity between autoimmune anti-U1 snRNP antibodies and neutralizing epitopes of HIV-1 gp120/41.

Douvas A, Takehana Y.

AIDS Res Hum Retroviruses. 1994 Mar;10(3):253-62.

PMID:
7517148
8.

Targeting human immunodeficiency virus type 1 with antibodies derived from patients with connective tissue disease.

Scherl M, Posch U, Obermoser G, Ammann C, Sepp N, Ulmer H, Dierich MP, Stoiber H, Falkensammer B.

Lupus. 2006;15(12):865-72.

PMID:
17211992
9.

Shared antigenic epitopes on the V3 loop of HIV-1 gp120 and proteins on activated human T cells.

Trujillo JR, Rogers RA, Brain JD.

Virology. 1998 Jun 20;246(1):53-62.

10.

Cross-reactive response to human immunodeficiency virus type 1 (HIV-1) gp120 and HLA class I heavy chains induced by receipt of HIV-1-derived envelope vaccines.

De Santis C, Robbioni P, Longhi R, Lopalco L, Siccardi AG, Beretta A, Roberts NJ Jr.

J Infect Dis. 1993 Dec;168(6):1396-403.

PMID:
8245524
11.

Epitope specificity of anti-HIV antibodies in human and murine autoimmune diseases.

Fraziano M, Montesano C, Lombardi VR, Sammarco I, De Pisa F, Mattei M, Valesini G, Pittoni V, Colizzi V.

AIDS Res Hum Retroviruses. 1996 Apr 10;12(6):491-6.

PMID:
8679304
12.

Presence of antilamin antibodies in sera of patients with systemic lupus erythematosus.

Wang H, Cui J, Wang X, Wang Y.

Chin Med Sci J. 1995 Dec;10(4):223-5.

PMID:
8745583
13.

Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.

Moore JP, Sattentau QJ, Yoshiyama H, Thali M, Charles M, Sullivan N, Poon SW, Fung MS, Traincard F, Pinkus M, et al.

J Virol. 1993 Oct;67(10):6136-51.

14.

Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120.

Akerblom L, Hinkula J, Broliden PA, Mäkitalo B, Fridberger T, Rosen J, Villacres-Eriksson M, Morein B, Wahren B.

AIDS. 1990 Oct;4(10):953-60.

PMID:
1702001
15.

Cross-reactive antibodies between HIV-gp120 and platelet gpIIIa (CD61) in HIV-related immune thrombocytopenic purpura.

Bettaieb A, Oksenhendler E, Duedari N, Bierling P.

Clin Exp Immunol. 1996 Jan;103(1):19-23.

16.

CD4-imitating human antibodies in HIV infection and anti-idiotypic vaccination.

Deckert PM, Ballmaier M, Lang S, Deicher H, Schedel I.

J Immunol. 1996 Jan 15;156(2):826-33.

PMID:
8543839
18.

Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.

Richardson TM Jr, Stryjewski BL, Broder CC, Hoxie JA, Mascola JR, Earl PL, Doms RW.

J Virol. 1996 Feb;70(2):753-62.

19.

Characterization of reactivity of monoclonal autoantibodies with renal antigens in experimental lupus nephritis.

Kootstra JC, Veninga A, Baelde JJ, van Eendenburg J, de Heer E, Bruijn JA.

J Clin Lab Immunol. 1996;48(5):201-18.

PMID:
9394243
20.

Human antibodies to immunodominant C5 region of HIV-1 gp120 cross-react with HLA class I on activated cells.

de Santis C, Lopalco L, Robbioni P, Longhi R, Rappocciolo G, Siccardi AG, Beretta A.

AIDS Res Hum Retroviruses. 1994 Feb;10(2):157-62.

PMID:
7515259

Supplemental Content

Support Center